Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

PL EN


Preferences help
enabled [disable] Abstract
Number of results
2013 | 18 | 18 | 149-156

Article title

INVESTIGATION OF FENOFIBRATE DISSOLUTION RATE INCORPORATED ON SOLID DISPERSIONS INTO CHITOSAN

Content

Title variants

Languages of publication

EN

Abstracts

EN
The aim of the study was to investigate the effect of chitosan on the dissolution of fenofibrate incorporated into this polymer carrier. The study investigated fenofibrate in physical mixtures at the drug to polymer ratio of 1:9, 3:7, and 5:5. The solubility investigation was performed by means of a dynamic method in a dissolution apparatus; mean amount of dissolved fenofibrate and the drug to polymer quantitative ratio in which the solid dispersion possessed the most beneficial properties improving the drug solubility were calculated. The study revealed a multi-fold increase (from 13 to 70 times) in fenofibrate solubility in the presence of chitosan, which increased with duration of the study and with increasing percentage of the polymer in formulations. The dissolution rates of fenofibrate in the presence of chitosan at the weight ratio 1:9 increased with the increment of the molecular weight of the chitosan.
The obtained results may help develop new technologies for fenofibrate preparations with chitosan, with better solubility characteristics, and thus increased bioavailability of the drug.

Contributors

  • Faculty of Pharmacy, "Silesian Piast" memorial Medical University of Wroclaw
  • Faculty of Pharmacy, "Silesian Piasts" memorial Medical University of Wroclaw
author
  • Faculty of Pharmacy, "Silesian Piasts" memorial Medical University of Wroclaw
author
  • Faculty of Pharmacy, "Silesian Piasts" memorial Medical University of Wroclaw

References

  • 1. Granero G.E., Ramachandran Ch., Amidon G.L.; (2005) Dissolution and Solubility of Fenofibrate in Sodium Lauryl Sulfate Solutions. Drug Development and Industrial Pharmacy.31,pp 917-922.
  • 2. Tsimihodimos V. Miltiadous G.,Daskalopoulou S.S. et al.; (2005) Fenofibrate:Metabolic and Pleiotropic Effects. Current Vascular Pharmacology 3,pp. 87-98.
  • 3. Woskowicz M.; (2008) Biofarmaceutyczny system klasyfikacji (BCS) jako nowoczesna metoda oceny właściwości fizykochemicznych i farmakokinetycznych środków leczniczych. Farmacja Polska 64, pp. 191-195.
  • 4. Amidon G.L., Lennernäs H., Shah V.P., Crison J.R.; (1995) A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability; Pharm. Res. 12 (3), pp. 413-420.
  • 5. Dhirendra K., Lewis S., Udupa N., Atin K.;(2009) Solid dispersions: a review; Pak. J. Pharm. Sci., 22 (2), 234-246.
  • 6. Patel T., Patel L.D., Makwana S.;(2010) Enhancement of dissolution of fenofibrate by solid dispersion technique; Int. J. Res. Pharm. Sci., 1,(2),pp. 127-132.
  • 7. Farmakopea Polska VII;(2007) Uwalnianie substancji ze stałych postaci leku; suplement, pp. 1417-1425.8. 8.Yusong W., Toshihiro S., Takashi S., Satoshi I., Kensuke S.;(2006) Layered structure hydrophobic ally modified chitosan derivatives; Carbohydrate Polymers 63, pp.493–499.

Document Type

article

Publication order reference

Identifiers

YADDA identifier

bwmeta1.element.psjd-bc74f4df-5ee2-4deb-885f-9779488a0daa
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.